Evidence map›Paper›PMID 33733436›Full record

ArticlePharmacopsychiatry2021

Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19?

Udo Bonnet, Georg Juckel, Norbert Scherbaum, Martin Schaefer, Bernhard Kis, Simon Cohen, Jens Kuhn

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Pharmacopsychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Udo BonnetDepartment of Psychiatry, Psychotherapy, and Psychosomatic Medicine, Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching Hospital of the University of Duisburg-Essen, Essen, Germany.
Georg JuckelDepartment of Psychiatry, Ruhr University Bochum, LWL University Hospital, Bochum, Germany.
Norbert ScherbaumLVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Martin SchaeferDepartment of Psychiatry, Psychotherapy, Psychosomatics and Addiction Medicine, Evang. Kliniken Essen-Mitte, Essen, Germany.
Bernhard KisDepartment of Psychiatry, Psychotherapy and Psychosomatics, St. Elisabeth Hospital Niederwenigern, Contilia Group, Hattingen, Germany.
Simon CohenKlinik für Psychiatrie, Psychotherapie und Gerontopsychiatrie, HELIOS Marien Klinik, Duisburg, Germany.
Jens KuhnDepartment of Psychiatry and Psychotherapy, University Hospital Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antipsychotic AgentsClinical DeteriorationCOVID-19 Drug TreatmentAntidepressive AgentsFluvoxamineHumansOutpatientsSARS-CoV-2Antidepressive AgentsAntipsychotic AgentsFluvoxamine

Identifiers

PMID33733436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.